These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21221851)

  • 1. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
    Gruber FX; Lundán T; Goll R; Silye A; Mikkola I; Rekvig OP; Knuutila S; Remes K; Gedde-Dahl T; Porkka K; Hjorth-Hansen H
    Med Oncol; 2012 Mar; 29(1):219-26. PubMed ID: 21221851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
    Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
    Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib.
    Gaillard JB; Arnould C; Bravo S; Donadio D; Exbrayat C; Jourdan E; Reboul D; Chiesa J; Lavabre-Bertrand T
    Mol Cancer Ther; 2010 Nov; 9(11):3083-9. PubMed ID: 21045136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
    Qin Y; Chen S; Jiang B; Jiang Q; Jiang H; Li J; Li L; Lai Y; Liu Y; Huang X
    Ann Hematol; 2011 Jan; 90(1):47-52. PubMed ID: 20697894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in ABL kinase domain are associated with inferior progression-free survival.
    Sharma P; Mohanty S; Kochupillai V; Kumar L
    Leuk Lymphoma; 2010 Jun; 51(6):1072-8. PubMed ID: 20367437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
    Branford S; Rudzki Z; Walsh S; Parkinson I; Grigg A; Szer J; Taylor K; Herrmann R; Seymour JF; Arthur C; Joske D; Lynch K; Hughes T
    Blood; 2003 Jul; 102(1):276-83. PubMed ID: 12623848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
    Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.
    Meggyesi N; Kalmár L; Fekete S; Masszi T; Tordai A; Andrikovics H
    Med Oncol; 2012 Sep; 29(3):2136-42. PubMed ID: 22038725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
    Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
    Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
    Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
    PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
    Nardi V; Azam M; Daley GQ
    Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
    von Bubnoff N; Manley PW; Mestan J; Sanger J; Peschel C; Duyster J
    Blood; 2006 Aug; 108(4):1328-33. PubMed ID: 16614241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
    Sherbenou DW; Hantschel O; Kaupe I; Willis S; Bumm T; Turaga LP; Lange T; Dao KH; Press RD; Druker BJ; Superti-Furga G; Deininger MW
    Blood; 2010 Oct; 116(17):3278-85. PubMed ID: 20519627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
    Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
    Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
    Press RD; Willis SG; Laudadio J; Mauro MJ; Deininger MW
    Blood; 2009 Sep; 114(13):2598-605. PubMed ID: 19625707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
    Shah NP; Nicoll JM; Nagar B; Gorre ME; Paquette RL; Kuriyan J; Sawyers CL
    Cancer Cell; 2002 Aug; 2(2):117-25. PubMed ID: 12204532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.